Paul Dunn Ph.D., ASHI Director and HLA Advisor, has 13 years experience in tissue typing and the development of HLA typing technologies. Paul graduated with BSc(hons) in Biochemistry from the University of London and a PhD in Protein Biochemistry from the University of Sussex. Following post-doctoral fellowships at the University of Cambridge in Molecular Biology and Genetic Engineering Paul moved into the field of Histocompatibility, firstly in the development of DNA sequencing for HLA Typing at UK Transplant in Bristol UK (1995-2000). Paul was then recruited by The National Blood Service as EFI Director of the tissue typing laboratory and British Bone Marrow Registry in Bristol (2000-2005). In the beginning of 2005 Paul moved to New Zealand as ASHI Director of the National Tissue Typing Laboratory and in July 2008 was recruited by GMSbiotech to oversee ASHI certification and to advise on HLA typing and technologies. Paul has more than 50 articles published in the fields of protein biochemistry, gene analysis and expression, HLA typing and transfusion.
Dr. Ramesh Ramakrishnan, Dr. Ramakrishnan holds the position of senior vice president of R&D at Talis Biomedical Corporation since May of 2019, where he oversees development of the company’s technology platform and execution of the product portfolio directed at molecular diagnostics employing nucleic acid testing. Before Talis BioMedical he was the Senior Vice President of R&D and Operations at Dovetail Genomics, and the Executive Vice President of R&D at Fluidigm Corporation, California.
His passion is in developing new technologies and to apply the simplest solutions to solve critical challenges. He has more than 25 years of experience in the development and commercialization of genomic products and solutions in biotechnology and clinical research, particularly in molecular diagnostics, through previous employments at Astra Research Center, India, Vysis Inc, Motorola Life Sciences, Nanosphere Inc. and Fluidigm Corporation. In addition, he has extensive experience in development of platforms over his career at Fluidigm Corporation and Nanosphere Inc.
His deep experience in science has spanned a wide variety of different cutting edge and emerging technologies. He obtained his PhD through a Fulbright scholarship, and has been associated with the Fulbright program ever since, including as a board of director of the Fulbright Association and Fulbright Academy of Science and Technology, a member of their Executive Committee and as their Secretary, with a view to assist in the application of science to help solve basic human needs.